|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismRPE65 gene transference |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX103 in Patients With X-Linked Retinoschisis (XLRS)
The goal of this study is to evaluate the safety and efficacy of LX103 treatment of X-linked retinoschisis. This study will enroll subjects aged ≥ 6 years old to receive a single unilateral intravitreal (IVT) injection of LX103 to evaluate its safety and efficacy.
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
The goal of this study is to evaluate the safety and efficacy of LX102-C01 treatment of nAMD. This study will enroll subjects aged ≥ 50 years old to receive a single unilateral intravitreal (IVT) injection of LX102-C01 to evaluate its safety and efficacy.
在新生血管性年龄相关性黄斑变性受试者中评价视网膜下注射LX102安全性和有效性的多中心、多阶段临床研究
[Translation] A multi-center, multi-stage clinical study to evaluate the safety and efficacy of subretinal injection of LX102 in subjects with neovascular age-related macular degeneration
评价视网膜下注射LX102治疗新生血管性年龄相关性黄斑变性(nAMD)的总体安全性和有效性
[Translation] To evaluate the overall safety and efficacy of subretinal injection of LX102 in the treatment of neovascular age-related macular degeneration (nAMD)
100 Clinical Results associated with Innostellar Biotherapeutics Co., Ltd.Ltd.
0 Patents (Medical) associated with Innostellar Biotherapeutics Co., Ltd.Ltd.
100 Deals associated with Innostellar Biotherapeutics Co., Ltd.Ltd.
100 Translational Medicine associated with Innostellar Biotherapeutics Co., Ltd.Ltd.